New erythrocyte-stimulating factor analogues

A technology of erythropoietin and analogs, which is applied in the field of recombinant plasmids and host cells, erythropoietin analogs or variants, and can solve the problem of decreased activity in vitro

Active Publication Date: 2013-01-09
SHENYANG SUNSHINE PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, another study showed that if the asparagine or serine residues as glycosylation sites were mutated to remove N-linked or O-linked oligosaccharide chains individually or together, it would make the mammalian cells The in vitro activity of mutant proteins produced in the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New erythrocyte-stimulating factor analogues
  • New erythrocyte-stimulating factor analogues
  • New erythrocyte-stimulating factor analogues

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1: Construction of human erythropoietin analog DNA fragments

[0047] There are 3 natural N-glycosylation sites in the amino acid sequence of human erythropoietin, which are located at positions 24, 38 and 83, respectively. 28, 30, 88 (see figure 1 ).

[0048] Combinations between mutation groups are performed on the above sites, such as constructing [Asn 2 Gly 3 Thr 4 ], [Asn 28 Thr 30 ], [Asn 88 Gly 89 Ser 90 ], adding N-glycosylation sites at positions 2, 28, and 88, and enhancing the glycosylation at this position by changing the amino acid sequence of the middle position or the position before the glycosylation site.

[0049] See SEQ ID NOS: 2-85 for primers that additionally add N-glycosylation site mutant moieties. Using these primers, the erythropoietin analog DNA fragment after mutation can be obtained by performing polymerase chain reaction (PCR) with erythropoietin DNA as a template. Template DNA was derived from a native EPO cDNA library. ...

Embodiment 2

[0133] Example 2: Asn 2 Gly 3 Thr 4 Preparation of EPO

[0134] A. Construction, screening and culture of engineered cells

[0135] The plasmid pEC4-N1 constructed according to the method of Example 1 was transfected into CHO cells, and the host cells were purchased from the American Type Culture Collection (ATCC) and were dihydrofolate reductase-deficient Chinese hamster ovary cells (CHO dhfr-). The cells were cultured in a 100mm petri dish, and when the cells were 60-95% full, the cells were rinsed with serum-free medium, and a transfection mixture consisting of 5ml of serum-free medium, 10μg pEC4-N1, and 60μg lipofectamine was added. , cultured at 37°C for 4 hours, aspirated the medium, added MEM medium containing 5% fetal bovine serum, and cultured at 37°C overnight. MTX was then added to the medium, and the culture was continued for 10-14 days until resistant clones appeared. Cells cultured from resistant clones were digested with trypsin, and the concentration of MT...

Embodiment 3

[0144] Example 3: Asn 3 Phe 4 Ser 5 Preparation of EPO

[0145] A. Construction, screening and culture of engineered cells

[0146] The plasmid pEC4-N2 constructed according to the method of Example 1 was transfected into CHO cells, and the host cells were purchased from the American Type Culture Collection (ATCC) and were dihydrofolate reductase-deficient Chinese hamster ovary cells (CHO dhfr-). The cells were cultured in a 100mm petri dish. When the cells grew to 60-95% full, the cells were rinsed with serum-free medium, and a transfection mixture consisting of 5ml of serum-free medium, 10μg pEC4-N2, and 60μg lipoFectamin was added. , cultured at 37°C for 4 hours, aspirated the medium, added MEM medium containing 5% fetal bovine serum, and cultured at 37°C overnight. MTX was then added to the medium, and the culture was continued for 10-14 days until resistant clones appeared. Cells cultured from resistant clones were digested with trypsin, and the concentration of MTX ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an erythropoietin analog with at least one extra glycosylation sites or a variant thereof. The invention also relates to a DNA sequence for coding the erythropoietin analog or the variant thereof, and a recombinant plasmid and a host cell for expressing the analog or the variant thereof.

Description

technical field [0001] The present invention belongs to the technical field of genetic engineering, in particular to an erythropoietin analog or a variant thereof with at least one additional glycosylation site. The present invention also relates to DNA sequences encoding said erythropoietin analogs or variants thereof, as well as recombinant plasmids and host cells expressing the analogs or variants thereof. Background of the Invention [0002] Erythropoietin (erythropoietin, EPO) is the first hematopoietic growth factor to be discovered and applied in clinic. As early as 1906, Carnot et al. found that rabbits would produce a substance in the peripheral blood after blood loss that could act on the hematopoietic system to accelerate erythropoiesis, thus suggesting that there is a humoral factor that regulates hematopoiesis in a feedback manner. After more than 30 years, this view was confirmed, and this factor was named erythropoietin. Erythropoietin, also known as hematop...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/505C12N15/12C12N15/79A61K38/18A61P7/06
Inventor 娄竞耿建玲张杰侯绪凤赵会林陆军苏冬梅胡金东
Owner SHENYANG SUNSHINE PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap